Compare XAIR & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XAIR | SBFM |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | 50 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 4.9M |
| IPO Year | 2015 | N/A |
| Metric | XAIR | SBFM |
|---|---|---|
| Price | $0.49 | $0.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $7.00 |
| AVG Volume (30 Days) | ★ 260.5K | 148.2K |
| Earning Date | 06-16-2026 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,705,000.00 | N/A |
| Revenue This Year | $122.00 | $40.47 |
| Revenue Next Year | $58.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 219.67 | N/A |
| 52 Week Low | $0.15 | $0.28 |
| 52 Week High | $3.78 | $2.43 |
| Indicator | XAIR | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 32.89 |
| Support Level | $0.44 | N/A |
| Resistance Level | $0.60 | $1.42 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 41.80 | 12.47 |
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.